|
Daniel's Biotech Briefing
Distilled Bio uses AI to process and generate content for you. Verify important details using the linked sources.
HTL Biotechnology opened its pharmaceutical-grade polynucleotide plant in France, while neurology startups raised $450 million and Windward Bio debuted on Nasdaq.
The top 9 stories from Fri Nov 13, 2026 07:09 AM to Mon Nov 16, 2026 07:05 AM
Generated November 16, 2026 at 7:05 AM
|
|
|
#1 IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors Published 2026-11-15 IDEAYA Biosciences nominated IDE101, a potential first-in-class candidate targeting CDKN2A-deficient solid tumors, after preclinical activity alone and with RAS and PRMT5 inhibitors. Covered by: prnewswire.com |
#2 Innovative Immunology Biotech Windward Bio Lists on Nasdaq Published 2026-11-14 Windward Bio, a clinical-stage biotechnology company backed by Qiming Venture Partners, listed on Nasdaq on November 13, 2026, after pricing its IPO at $17 per share. Covered by: prnewswire.com, prnewswire.com, endpoints.news, fiercebiotech.com, insights.citeline.com |
#3 HTL Biotechnology launches HTL8, a production unit dedicated to pharmaceutical-grade polynucleotides (DNA) Published 2026-11-13 HTL Biotechnology inaugurated HTL8, a new production unit in Javené, France, dedicated to manufacturing pharmaceutical-grade polynucleotides. Covered by: prnewswire.com |
#4 Sofinnova closes second crossover fund at €725M for late-stage European biotechs Published 2026-11-16 Sofinnova Partners raised €725 million for its second crossover fund, targeting late-stage European biopharma and medtech companies. Covered by: endpoints.news, biopharmadive.com, fiercebiotech.com |
#5 Big Pharma-backed Seawolf surfaces with $100M to hand, $1.2B Sanofi DNA med pact Published 2026-11-16 Seawolf Therapeutics raised $100 million and signed a DNA therapeutics deal with Sanofi worth up to $1.2 billion. Covered by: fiercebiotech.com |
#6 This week in charts: Brain drugs are back on venture capitalists’ minds Published 2026-11-13 Five neurology-focused startups raised about $450 million in recent weeks, while investors responded cautiously to new cell therapy research. Covered by: biopharmadive.com |
#7 Ambrosia Biosciences Announces the Nonclinical Data Profiles of Two Oral Small Molecule Programs: A GLP-1 Receptor Agonist Intended for Once-Weekly Dosing and a GIP Receptor Antagonist Published 2026-11-15 Ambrosia Biosciences presented preclinical data on two oral drug candidates: a GLP-1 receptor agonist designed for weekly dosing and a GIP receptor antagonist. Covered by: prnewswire.com |
#8 Novo submits sickle cell drug; Flagship, Gates Foundation deepen ties Published 2026-11-13 Novo submitted a sickle cell drug, while Flagship and the Gates Foundation deepened their partnership. Covered by: biopharmadive.com |
#9 Flagship Pioneering Launches Flagship Origination Lab in London to Create AI-Native Platform Companies in the U.K. Published 2026-11-16 Flagship Pioneering is launching a London origination lab with an initial £100 million commitment, expanding its company-creation model beyond Cambridge, Massachusetts. Covered by: prnewswire.com |